| Literature DB >> 34263659 |
Garima Shrivastava1, Alaa Aa Aljabali2, Seyed Hossein Shahcheraghi3, Marzieh Lotfi3, Madhur D Shastri4, Shakti D Shukla5, Dinesh K Chellappan6, Niraj Kumar Jha7, Krishnan Anand8, Harish Dureja9, Ritesh M Pabari10, Vijay Mishra11, Abdulmajeed G Almutary12, Abdullah M Alnuqaydan12, Nitin Charbe13, Parteek Prasher14, Poonam Negi15, Rohit Goyal15, Kamal Dua16, Gaurav Gupta17, Ángel Serrano-Aroca18, Bojlul Bahar19, Debmalya Barh20, Pritam Kumar Panda21, Kazuo Takayama22, Kenneth Lundstorm23, Paul McCarron24, Hamid Bakshi24, Murtaza M Tambuwala24.
Abstract
The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area.Entities:
Keywords: LIN28A; LIN28B; biomarker; prostate cancer; theranostic
Mesh：
Substances：
Year: 2021 PMID： 34263659 DOI： 10.2217/fon-2021-0247
Source DB: PubMed Journal: Future Oncol ISSN： 1479-6694 Impact factor: 3.404